Skip to main content

Harry Kupfer: German opera great dies aged 84

Harry Kupfer
Harry Kupfer

One of the world’s most celebrated opera directors, Germany’s Harry Kupfer, has died at the age of 84 in Berlin, his agency confirmed on Tuesday.

In a career spanning 44 years, Kupfer worked at opera houses across Germany and was chief director of Berlin’s iconic Komische Oper for more than two decades.

Born in 1935, Kupfer studied in Leipzig and first worked in then-communist East Germany.

But he rose to fame in 1978 with a production of Richard Wagner’s “The Flying Dutchman” at the world-renowned Bayreuth festival.

READ ALSO: Be vigilant against menace of road accidents in 2020, FRSC urges Nigerians

He took the reins at the Komische Oper three years later in 1981.

A student of Komische Oper founder Walter Felsenstein, Kupfer staged works by Mozart and Wagner and oversaw two world premieres at the opera house before bowing out in 2002.

He returned to Bayreuth in 1988, staging Wagner’s “Ring of the Nibelung” alongside Argentine-Israeli conductor Daniel Barenboim.

After the fall of the Berlin Wall, Kupfer cooperated with Barenboim again on an ambitious project to stage one Wagner opera a year over the course of a decade at the Berlin State Opera.

He continued to work until right up to his death, directing around the world and staging Georg Friederich Handel’s Poro in a triumphant return to the Komische Oper earlier this year.

VANGUARD

The post Harry Kupfer: German opera great dies aged 84 appeared first on Vanguard News.


by Emmanuel Okogba via Vanguard News https://ift.tt/2QBRJCQ Best Known Member of the Cabinet Wikipedia

Comments

Popular posts from this blog

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO:  COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...